Skip to content

A cohort study about the role of AR - V7 in evaluating the prognosis of prostate cancer receiving adjuvant hormonal therapy

A cohort study about the role of AR - V7 in evaluating the prognosis of prostate cancer receiving adjuvant hormonal therapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015334
Enrollment
Unknown
Registered
2018-03-24
Start date
2018-04-01
Completion date
Unknown
Last updated
2018-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Sponsors

Department of Urology Laboratory, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Oligometastasis was found in preoperative imaging or postoperative pathological examination of prostate cancer radical surgery; 2. Palliative tumor-reducing surgery for prostate cancer has been performed in patients with advanced metastatic prostate cancer; 3. The pathological examination of prostate cancer after radical mastectomy is positive, and because of age or physical condition factors, or considering the side effects of radiotherapy, patients who cannot or refuse to receive radiotherapy; In accordance with one of the above conditions, patients undergoing surgical treatment are assisted with endocrine therapy.

Exclusion criteria

Exclusion criteria: 1. Patients with severe heart, lung, liver and kidney diseases; 2. patients who refused treatment; 3. Patients who were not treated according to the doctors requirements.

Design outcomes

Primary

MeasureTime frame
AR-V7 Prostate specific antigen;

Countries

China

Contacts

Public ContactYe Zhangqun

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

zhangqun_ye@163.com+86 027-83663460

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026